Terms: = Lung cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Prognosis
4 results:
1. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract] [Full Text] [Related]
2. Overexpression of
Tran OT; Tadesse S; Chu C; Kidane D
Tumour Biol; 2020 May; 42(5):1010428320918404. PubMed ID: 32364878
[TBL] [Abstract] [Full Text] [Related]
3. Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma.
Losi L; Bertolini F; Guaitoli G; Fabbiani L; Banchelli F; Ambrosini-Spaltro A; Botticelli L; Scurani L; Baldessari C; Barbieri F; Cascinu S; Maiorana A
Int J Oncol; 2019 Nov; 55(5):1157-1164. PubMed ID: 31545419
[TBL] [Abstract] [Full Text] [Related]
4. Expression of MSH2 and msh6 on a tissue microarray in patients with osteosarcoma.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Dec; 34(12):6961-72. PubMed ID: 25503122
[TBL] [Abstract] [Full Text] [Related]
